In cultured adult breast cancer cells, COX inhibitors were found to reduce aromatase mRNA expression and enzyme activity in a dose-dependent manner, suggesting potential applications in hormone-dependent breast cancer therapies (30). Here, CYP19A1 is linked to breast carcinoma.